Comparative proteomics identifies Schlafen 5 (SLFN5) as a herpes simplex virus restriction factor that suppresses viral transcription.


Journal

Nature microbiology
ISSN: 2058-5276
Titre abrégé: Nat Microbiol
Pays: England
ID NLM: 101674869

Informations de publication

Date de publication:
02 2021
Historique:
received: 06 02 2020
accepted: 03 11 2020
pubmed: 13 1 2021
medline: 23 4 2021
entrez: 12 1 2021
Statut: ppublish

Résumé

Intrinsic antiviral host factors confer cellular defence by limiting virus replication and are often counteracted by viral countermeasures. We reasoned that host factors that inhibit viral gene expression could be identified by determining proteins bound to viral DNA (vDNA) in the absence of key viral antagonists. Herpes simplex virus 1 (HSV-1) expresses E3 ubiquitin-protein ligase ICP0 (ICP0), which functions as an E3 ubiquitin ligase required to promote infection. Cellular substrates of ICP0 have been discovered as host barriers to infection but the mechanisms for inhibition of viral gene expression are not fully understood. To identify restriction factors antagonized by ICP0, we compared proteomes associated with vDNA during HSV-1 infection with wild-type virus and a mutant lacking functional ICP0 (ΔICP0). We identified the cellular protein Schlafen family member 5 (SLFN5) as an ICP0 target that binds vDNA during HSV-1 ΔICP0 infection. We demonstrated that ICP0 mediates ubiquitination of SLFN5, which leads to its proteasomal degradation. In the absence of ICP0, SLFN5 binds vDNA to repress HSV-1 transcription by limiting accessibility of RNA polymerase II to viral promoters. These results highlight how comparative proteomics of proteins associated with viral genomes can identify host restriction factors and reveal that viral countermeasures can overcome SLFN antiviral activity.

Identifiants

pubmed: 33432153
doi: 10.1038/s41564-020-00826-3
pii: 10.1038/s41564-020-00826-3
pmc: PMC7856100
mid: NIHMS1643765
doi:

Substances chimiques

Cell Cycle Proteins 0
DNA, Viral 0
Immediate-Early Proteins 0
SLFN5 protein, human 0
Ubiquitin-Protein Ligases EC 2.3.2.27
Vmw110 protein, Human herpesvirus 1 EC 2.3.2.27
RNA Polymerase II EC 2.7.7.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

234-245

Subventions

Organisme : NINDS NIH HHS
ID : K08 NS109332
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI115104
Pays : United States
Organisme : NIAID NIH HHS
ID : F32 AI138432
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS082240
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_12014/5
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : F32 AI147587
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA115299
Pays : United States

Références

Malim, M. H. & Bieniasz, P. D. HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. 2, a006940 (2012).
pubmed: 22553496 pmcid: 3331687 doi: 10.1101/cshperspect.a006940
Gu, H. & Zheng, Y. Role of ND10 nuclear bodies in the chromatin repression of HSV-1. Virol. J. 13, 62 (2016).
pubmed: 27048561 pmcid: 4822283 doi: 10.1186/s12985-016-0516-4
Tavalai, N. & Stamminger, T. Intrinsic cellular defense mechanisms targeting human cytomegalovirus. Virus Res. 157, 128–133 (2011).
pubmed: 20934469 doi: 10.1016/j.virusres.2010.10.002
Glass, M. & Everett, R. D. Components of promyelocytic leukemia nuclear bodies (ND10) act cooperatively to repress herpesvirus infection. J. Virol. 87, 2174–2185 (2013).
pubmed: 23221561 pmcid: 3571464 doi: 10.1128/JVI.02950-12
Crow, M. S., Lum, K. K., Sheng, X., Song, B. & Cristea, I. M. Diverse mechanisms evolved by DNA viruses to inhibit early host defenses. Crit. Rev. Biochem. Mol. Biol. 51, 452–481 (2016).
pubmed: 27650455 pmcid: 5285405 doi: 10.1080/10409238.2016.1226250
Rajsbaum, R. & García-Sastre, A. Viral evasion mechanisms of early antiviral responses involving regulation of ubiquitin pathways. Trends Microbiol. 21, 421–429 (2013).
pubmed: 23850008 pmcid: 3740364 doi: 10.1016/j.tim.2013.06.006
Dybas, J. M., Herrmann, C. & Weitzman, M. D. Ubiquitination at the interface of tumor viruses and DNA damage responses. Curr. Opin. Virol. 32, 40–47 (2018).
pubmed: 30261451 pmcid: 6263849 doi: 10.1016/j.coviro.2018.08.017
Colomer-Lluch, M., Ruiz, A., Moris, A. & Prado, J. G. Restriction factors: from intrinsic viral restriction to shaping cellular immunity against HIV-1. Front. Immunol. 9, 2876 (2018).
pubmed: 30574147 pmcid: 6291751 doi: 10.3389/fimmu.2018.02876
Simon, V., Bloch, N. & Landau, N. R. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat. Immunol. 16, 546–553 (2015).
pubmed: 25988886 pmcid: 6908429 doi: 10.1038/ni.3156
Komatsu, T., Nagata, K. & Wodrich, H. The role of nuclear antiviral factors against invading DNA viruses: the immediate fate of incoming viral genomes. Viruses 8, 290 (2016).
pmcid: 5086622 doi: 10.3390/v8100290
Bieniasz, P. D. Restriction factors: a defense against retroviral infection. Trends Microbiol. 11, 286–291 (2003).
pubmed: 12823946 doi: 10.1016/S0966-842X(03)00123-9
Harris, R. S., Hultquist, J. F. & Evans, D. T. The restriction factors of human immunodeficiency virus. J. Biol. Chem. 287, 40875–40883 (2012).
pubmed: 23043100 pmcid: 3510791 doi: 10.1074/jbc.R112.416925
Boutell, C. & Everett, R. D. Regulation of alphaherpesvirus infections by the ICP0 family of proteins. J. Gen. Virol. 94, 465–481 (2013).
pubmed: 23239572 doi: 10.1099/vir.0.048900-0
Knipe, D. M. & Cliffe, A. Chromatin control of herpes simplex virus lytic and latent infection. Nat. Rev. Microbiol. 6, 211–221 (2008).
pubmed: 18264117 doi: 10.1038/nrmicro1794
Cai, W. & Schaffer, P. A. Herpes simplex virus type 1 ICP0 regulates expression of immediate-early, early, and late genes in productively infected cells. J. Virol. 66, 2904–2915 (1992).
pubmed: 1313909 pmcid: 241049 doi: 10.1128/jvi.66.5.2904-2915.1992
Rodríguez, M. C., Dybas, J. M., Hughes, J., Weitzman, M. D. & Boutell, C. The HSV-1 ubiquitin ligase ICP0: modifying the cellular proteome to promote infection. Virus Res. 285, 198015 (2020).
pubmed: 32416261 pmcid: 7303953 doi: 10.1016/j.virusres.2020.198015
Boutell, C. & Everett, R. D. The herpes simplex virus type 1 (HSV-1) regulatory protein ICP0 interacts with and ubiquitinates p53. J. Biol. Chem. 278, 36596–36602 (2003).
pubmed: 12855695 doi: 10.1074/jbc.M300776200
Everett, R. D., Orr, A. & Preston, C. M. A viral activator of gene expression functions via the ubiquitin–proteasome pathway. EMBO J. 17, 7161–7169 (1998).
pubmed: 9857173 pmcid: 1171062 doi: 10.1093/emboj/17.24.7161
Lium, E. K. & Silverstein, S. Mutational analysis of the herpes simplex virus type 1 ICP0 C3HC4 zinc ring finger reveals a requirement for ICP0 in the expression of the essential α27 gene. J. Virol. 71, 8602–8614 (1997).
pubmed: 9343218 pmcid: 192324 doi: 10.1128/jvi.71.11.8602-8614.1997
Parkinson, J., Lees-Miller, S. P. & Everett, R. D. Herpes simplex virus type 1 immediate-early protein Vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. J. Virol. 73, 650–657 (1999).
pubmed: 9847370 pmcid: 103871 doi: 10.1128/JVI.73.1.650-657.1999
Lees-Miller, S. P. et al. Attenuation of DNA-dependent protein kinase activity and its catalytic subunit by the herpes simplex virus type 1 transactivator ICP0. J. Virol. 70, 7471–7477 (1996).
pubmed: 8892865 pmcid: 190814 doi: 10.1128/jvi.70.11.7471-7477.1996
Chaurushiya, M. S. et al. Viral E3 ubiquitin ligase-mediated degradation of a cellular E3: viral mimicry of a cellular phosphorylation mark targets the RNF8 FHA domain. Mol. Cell 46, 79–90 (2012).
pubmed: 22405594 pmcid: 3648639 doi: 10.1016/j.molcel.2012.02.004
Lilley, C. E. et al. A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses. EMBO J. 29, 943–955 (2010).
pubmed: 20075863 pmcid: 2837166 doi: 10.1038/emboj.2009.400
Chelbi-Alix, M. K. & de Thé, H. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18, 935–941 (1999).
pubmed: 10023669 doi: 10.1038/sj.onc.1202366
Everett, R. D. et al. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J. Virol. 72, 6581–6591 (1998).
pubmed: 9658103 pmcid: 109835 doi: 10.1128/JVI.72.8.6581-6591.1998
Perusina Lanfranca, M., Mostafa, H. H. & Davido, D. J. Two overlapping regions within the N-terminal half of the herpes simplex virus 1 E3 ubiquitin ligase ICP0 facilitate the degradation and dissociation of PML and dissociation of Sp100 from ND10. J. Virol. 87, 13287–13296 (2013).
pubmed: 24089549 pmcid: 3838275 doi: 10.1128/JVI.02304-13
Lukashchuk, V. & Everett, R. D. Regulation of ICP0-null mutant herpes simplex virus type 1 infection by ND10 components ATRX and hDaxx. J. Virol. 84, 4026–4040 (2010).
pubmed: 20147399 pmcid: 2849514 doi: 10.1128/JVI.02597-09
Orzalli, M. H., DeLuca, N. A. & Knipe, D. M. Nuclear IFI16 induction of IRF-3 signaling during herpesviral infection and degradation of IFI16 by the viral ICP0 protein. Proc. Natl Acad. Sci. USA 109, E3008–E3017 (2012).
pubmed: 23027953 doi: 10.1073/pnas.1211302109
Everett, R. D., Earnshaw, W. C., Findlay, J. & Lomonte, P. Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110. EMBO J. 18, 1526–1538 (1999).
pubmed: 10075924 pmcid: 1171241 doi: 10.1093/emboj/18.6.1526
Lomonte, P., Sullivan, K. F. & Everett, R. D. Degradation of nucleosome-associated centromeric histone H3-like protein CENP-A induced by herpes simplex virus type 1 protein ICP0. J. Biol. Chem. 276, 5829–5835 (2001).
pubmed: 11053442 doi: 10.1074/jbc.M008547200
Lomonte, P. & Morency, E. Centromeric protein CENP-B proteasomal degradation induced by the viral protein ICP0. FEBS Lett. 581, 658–662 (2007).
pubmed: 17258208 doi: 10.1016/j.febslet.2007.01.027
Perusina Lanfranca, M., Mostafa, H. H. & Davido, D. J. HSV-1 ICP0: an E3 ubiquitin ligase that counteracts host intrinsic and innate immunity. Cells 3, 438–454 (2014).
doi: 10.3390/cells3020438
Alandijany, T. Host intrinsic and innate intracellular immunity during herpes simplex virus type 1 (HSV-1) infection. Front. Microbiol. 10, 2611 (2019).
pubmed: 31781083 pmcid: 6856869 doi: 10.3389/fmicb.2019.02611
Merkl, P. E., Orzalli, M. H. & Knipe, D. M. Mechanisms of host IFI16, PML, and Daxx protein restriction of herpes simplex virus 1 replication. J. Virol. 92, e00057-18 (2018).
pubmed: 29491153 pmcid: 5923075 doi: 10.1128/JVI.00057-18
Lilley, C. E., Chaurushiya, M. S., Boutell, C., Everett, R. D. & Weitzman, M. D. The intrinsic antiviral defense to incoming HSV-1 genomes includes specific DNA repair proteins and is counteracted by the viral protein ICP0. PLoS Pathog. 7, e1002084 (2011).
pubmed: 21698222 pmcid: 3116817 doi: 10.1371/journal.ppat.1002084
Cuchet-Lourenço, D. et al. SUMO pathway dependent recruitment of cellular repressors to herpes simplex virus type 1 genomes. PLoS Pathog. 7, e1002123 (2011).
pubmed: 21779164 pmcid: 3136452 doi: 10.1371/journal.ppat.1002123
Sirbu, B. M. et al. Analysis of protein dynamics at active, stalled, and collapsed replication forks. Genes Dev. 25, 1320–1327 (2011).
pubmed: 21685366 pmcid: 3127432 doi: 10.1101/gad.2053211
Dembowski, J. A. & DeLuca, N. A. Selective recruitment of nuclear factors to productively replicating herpes simplex virus genomes. PLoS Pathog. 11, e1004939 (2015).
pubmed: 26018390 pmcid: 4446364 doi: 10.1371/journal.ppat.1004939
Dembowski, J. A. & DeLuca, N. A. Temporal viral genome-protein interactions define distinct stages of productive herpesviral infection. mBio 9, e01182–18 (2018).
pubmed: 30018111 pmcid: 6050965 doi: 10.1128/mBio.01182-18
Reyes, E. D. et al. Identifying host factors associated with DNA replicated during virus infection. Mol. Cell. Proteomics 16, 2079–2097 (2017).
pubmed: 28972080 pmcid: 5724173 doi: 10.1074/mcp.M117.067116
Liu, F., Zhou, P., Wang, Q., Zhang, M. & Li, D. The Schlafen family: complex roles in different cell types and virus replication. Cell Biol. Int. 42, 2–8 (2018).
pubmed: 28460425 doi: 10.1002/cbin.10778
Mavrommatis, E., Fish, E. N. & Platanias, L. C. The Schlafen family of proteins and their regulation by interferons. J. Interferon Cytokine Res. 33, 206–210 (2013).
pubmed: 23570387 pmcid: 3624771 doi: 10.1089/jir.2012.0133
Katsoulidis, E. et al. Role of interferon α (IFNα)-inducible Schlafen-5 in regulation of Anchorage-independent growth and invasion of malignant melanoma cells. J. Biol. Chem. 285, 40333–40341 (2010).
pubmed: 20956525 pmcid: 3001013 doi: 10.1074/jbc.M110.151076
Sassano, A. et al. Human Schlafen 5 (SLFN5) is a regulator of motility and invasiveness of renal cell carcinoma cells. Mol. Cell. Biol. 35, 2684–2698 (2015).
pubmed: 26012550 pmcid: 4524119 doi: 10.1128/MCB.00019-15
Arslan, A. D. et al. Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma. Oncogene 36, 6006–6019 (2017).
pubmed: 28671669 pmcid: 5821504 doi: 10.1038/onc.2017.205
Li, M. et al. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature 491, 125–128 (2012).
pubmed: 23000900 pmcid: 3705913 doi: 10.1038/nature11433
Seong, R.-K. et al. Schlafen 14 (SLFN14) is a novel antiviral factor involved in the control of viral replication. Immunobiology 222, 979–988 (2017).
pubmed: 28734654 pmcid: 5990420 doi: 10.1016/j.imbio.2017.07.002
Yang, J.-Y. et al. Structure of Schlafen13 reveals a new class of tRNA/rRNA-targeting RNase engaged in translational control. Nat. Commun. 9, 1165 (2018).
pubmed: 29563550 pmcid: 5862951 doi: 10.1038/s41467-018-03544-x
Valdez, F. et al. Schlafen 11 restricts flavivirus replication. J. Virol. 93, e00104-19 (2019).
de la Casa-Esperón, E. From mammals to viruses: the Schlafen genes in developmental, proliferative and immune processes. Biomol. Concepts 2, 159–169 (2011).
pubmed: 25962026 doi: 10.1515/bmc.2011.018
Kulej, K. et al. Time-resolved global and chromatin proteomics during herpes simplex virus type 1 (HSV-1) infection. Mol. Cell. Proteomics 16, S92–S107 (2017).
pubmed: 28179408 pmcid: 5393384 doi: 10.1074/mcp.M116.065987
Schreiner, S. et al. Proteasome-dependent degradation of Daxx by the viral E1B-55K protein in human adenovirus-infected cells. J. Virol. 84, 7029–7038 (2010).
pubmed: 20484509 pmcid: 2898266 doi: 10.1128/JVI.00074-10
Dutrieux, J. et al. PML/TRIM19-dependent inhibition of retroviral reverse-transcription by Daxx. PLoS Pathog. 11, e1005280 (2015).
Bernassola, F. et al. Ubiquitin-dependent degradation of p73 is inhibited by PML. J. Exp. Med. 199, 1545–1557 (2004).
pubmed: 15184504 pmcid: 2211783 doi: 10.1084/jem.20031943
Louria-Hayon, I. et al. The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J. Biol. Chem. 278, 33134–33141 (2003).
pubmed: 12810724 doi: 10.1074/jbc.M301264200
Boutell, C. et al. A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence. PLoS Pathog. 7, e1002245 (2011).
pubmed: 21949651 pmcid: 3174244 doi: 10.1371/journal.ppat.1002245
Sloan, E. et al. Analysis of the SUMO2 proteome during HSV-1 Infection. PLoS Pathog. 11, e1005059 (2015).
pubmed: 26200910 pmcid: 4511656 doi: 10.1371/journal.ppat.1005059
Kumar, R., González-Prieto, R., Xiao, Z., Verlaan-de Vries, M. & Vertegaal, A. C. O. The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery. Nat. Commun. 8, 1809 (2017).
pubmed: 29180619 pmcid: 5703878 doi: 10.1038/s41467-017-01900-x
Neumann, B., Zhao, L., Murphy, K. & Gonda, T. J. Subcellular localization of the Schlafen protein family. Biochem. Biophys. Res. Commun. 370, 62–66 (2008).
pubmed: 18355440 doi: 10.1016/j.bbrc.2008.03.032
Taylor, K. E., Chew, M. V., Ashkar, A. A. & Mossman, K. L. Novel roles of cytoplasmic ICP0: proteasome-independent functions of the RING finger are required to block interferon-stimulated gene production but not to promote viral replication. J. Virol. 88, 8091–8101 (2014).
pubmed: 24807717 pmcid: 4097794 doi: 10.1128/JVI.00944-14
Lou, D. I. et al. An intrinsically disordered region of the DNA repair protein Nbs1 is a species-specific barrier to herpes simplex virus 1 in primates. Cell Host Microbe 20, 178–188 (2016).
pubmed: 27512903 pmcid: 4982468 doi: 10.1016/j.chom.2016.07.003
Alandijany, T. et al. Distinct temporal roles for the promyelocytic leukaemia (PML) protein in the sequential regulation of intracellular host immunity to HSV-1 infection. PLoS Pathog. 14, e1006769 (2018).
pubmed: 29309427 pmcid: 5757968 doi: 10.1371/journal.ppat.1006769
Geserick, P., Kaiser, F., Klemm, U., Kaufmann, S. H. E. & Zerrahn, J. Modulation of T cell development and activation by novel members of the Schlafen (slfn) gene family harbouring an RNA helicase-like motif. Int. Immunol. 16, 1535–1548 (2004).
pubmed: 15351786 doi: 10.1093/intimm/dxh155
Stabell, A. C. et al. Non-human primate Schlafen11 inhibits production of both host and viral proteins. PLoS Pathog. 12, e1006066 (2016).
pubmed: 28027315 pmcid: 5189954 doi: 10.1371/journal.ppat.1006066
Stow, N. D. & Stow, E. C. Isolation and characterization of a herpes simplex virus type 1 mutant containing a deletion within the gene encoding the immediate early polypeptide Vmw110. J. Gen. Virol. 67, 2571–2585 (1986).
pubmed: 3025339 doi: 10.1099/0022-1317-67-12-2571
Everett, R. D. Construction and characterization of herpes simplex virus type 1 mutants with defined lesions in immediate early gene 1. J. Gen. Virol. 70, 1185–1202 (1989).
pubmed: 2543774 doi: 10.1099/0022-1317-70-5-1185
Sirbu, B. M., Couch, F. B. & Cortez, D. Monitoring the spatiotemporal dynamics of proteins at replication forks and in assembled chromatin using isolation of proteins on nascent DNA. Nat. Protoc. 7, 594–605 (2012).
pubmed: 22383038 pmcid: 3671908 doi: 10.1038/nprot.2012.010
Stacklies, W., Redestig, H., Scholz, M., Walther, D. & Selbig, J. pcaMethods: a Bioconductor package providing PCA methods for incomplete data. Bioinformatics 23, 1164–1167 (2007).
pubmed: 17344241 doi: 10.1093/bioinformatics/btm069
Pascovici, D., Handler, D. C. L., Wu, J. X. & Haynes, P. A. Multiple testing corrections in quantitative proteomics: a useful but blunt tool. Proteomics 16, 2448–2453 (2016).
pubmed: 27461997 doi: 10.1002/pmic.201600044
Halford, W. P., Kemp, C. D., Isler, J. A., Davido, D. J. & Schaffer, P. A. ICP0, ICP4, or VP16 expressed from adenovirus vectors induces reactivation of latent herpes simplex virus type 1 in primary cultures of latently infected trigeminal ganglion cells. J. Virol. 75, 6143–6153 (2001).
pubmed: 11390616 pmcid: 114330 doi: 10.1128/JVI.75.13.6143-6153.2001
Poling, B. C., Price, A. M., Luftig, M. A. & Cullen, B. R. The Epstein–Barr virus miR-BHRF1 microRNAs regulate viral gene expression in cis. Virology 512, 113–123 (2017).
pubmed: 28950226 pmcid: 5653404 doi: 10.1016/j.virol.2017.09.015
Russo, J., Heck, A. M., Wilusz, J. & Wilusz, C. J. Metabolic labeling and recovery of nascent RNA to accurately quantify mRNA stability. Methods 120, 39–48 (2017).
pubmed: 28219744 pmcid: 5447484 doi: 10.1016/j.ymeth.2017.02.003
Price, A. M., Messinger, J. E. & Luftig, M. A. c-Myc represses transcription of Epstein–Barr virus latent membrane protein 1 early after primary B cell infection. J. Virol. 92, e01178–17 (2018).
pubmed: 29118124 pmcid: 5752943 doi: 10.1128/JVI.01178-17
Dölken, L. et al. High-resolution gene expression profiling for simultaneous kinetic parameter analysis of RNA synthesis and decay. RNA 14, 1959–1972 (2008).
pubmed: 18658122 pmcid: 2525961 doi: 10.1261/rna.1136108
Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 47, D442–D450 (2019).
pubmed: 30395289 doi: 10.1093/nar/gky1106

Auteurs

Eui Tae Kim (ET)

Division of Protective Immunity and Division of Cancer Pathobiology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Department of Microbiology and Immunology, Jeju National University School of Medicine, Jeju, Republic of Korea.

Joseph M Dybas (JM)

Division of Protective Immunity and Division of Cancer Pathobiology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Department of Biomedical and Health Informatics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Katarzyna Kulej (K)

Division of Protective Immunity and Division of Cancer Pathobiology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Biochemistry and Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Emigdio D Reyes (ED)

Division of Protective Immunity and Division of Cancer Pathobiology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Alexander M Price (AM)

Division of Protective Immunity and Division of Cancer Pathobiology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Lisa N Akhtar (LN)

Division of Protective Immunity and Division of Cancer Pathobiology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Division of Infectious Diseases, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Ann Orr (A)

MRC-University of Glasgow Center for Virus Research, Glasgow, UK.

Benjamin A Garcia (BA)

Department of Biochemistry and Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Epigenetics Program, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

Chris Boutell (C)

MRC-University of Glasgow Center for Virus Research, Glasgow, UK.

Matthew D Weitzman (MD)

Division of Protective Immunity and Division of Cancer Pathobiology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. weitzmanm@email.chop.edu.
Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. weitzmanm@email.chop.edu.
Epigenetics Program, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. weitzmanm@email.chop.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH